<DOC>
	<DOCNO>NCT00456859</DOCNO>
	<brief_summary>The CAP-KD trial prospective , multicenter , randomize , open-label , two-arm , parallel group comparison clinical trial conduct researcher-directed study ass efficacy Kremezin prevent progression CKD . We compare two group patient : receive conventional treatment alone receive treatment pair Kremezin .</brief_summary>
	<brief_title>Carbonaceous Oral Adsorbent 's Effects Progression Chronic Kidney Disease</brief_title>
	<detailed_description>A clinical trial evaluate efficacy oral carbonaceous adsorbent Kremezin prevent progression chronic kidney disease ( Carbonaceous Oral Adsorbent 's Effects Progression Chronic Kidney Disease [ CAP-KD ] trial ) predialysis patient . In trial compare two treatment : conventional treatment comprise ACEI and/or ARB together low-protein diet , combination treatment comprise conventional treatment pair Kremezin . Furthermore , compare QOL group patient</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<criteria>The subject outpatient . The subject 20 year age old time consent participate study . The subject 's serum creatinine value 5.0 mg/dl less time case registration . The inverse serum creatinine value , calculate use measurement four time point observation period occur within 48 week case registration , decrease , average , accord linearregression analysis perform case registration center . The subject 's blood pressure well control initial serum creatinine measurement observation period . The subject treat ACEI and/or ARB initial serum creatinine measurement observation period . The subject undergone lowprotein diet therapy ( &gt; 0.8 g/kg per day ) initial serum creatinine measurement observation period . The subject change type dose medication renal failure 4 week prior case registration . The subject participate thorough consultation inform purpose , description , expect adverse effect , risk study accord consent form , voluntarily sign informed consent form . The subject passage disorder gastrointestinal tract . The subject treat Kremezin within period initial measurement serum creatinine level prior case registration time study commencement . The subject rapid progressive glomerular nephritis , hydronephrosis , occlusive urinary tract injury , druginduced nephropathy , transplanted kidney . The subject complication severe hepatopathy , liver cirrhosis , severe infection , class III New York Heart Association ( NYHA ) congestive heart failure , severe arrhythmia , unstable angina . The subject cardiac infarction , cerebral infarction , cerebral hemorrhage within past 6 month . The subject present severe nephrotic syndrome ( serum albumin &lt; 2 g/dl ) . The subject currently pregnant , plan become pregnant study period . The subject abuse alcohol . The subject body weight less 80 % 160 % standard weight { [ height ( ) ] ^2 x 22 } . The subject significant difficulty control his/her blood sugar level within 3 month case registration ( hemoglobin [ Hb ] A1c &gt; 8.0 % one occasion ) . The subject progressive malignant tumor . The subject available study visit least per 2 month provide urine sample . The subject inappropriate participation study reason , determine investigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>chronic kidney disease</keyword>
	<keyword>oral carbonaceous adsorbent</keyword>
	<keyword>randomize clinical trial</keyword>
	<keyword>composite endpoint</keyword>
</DOC>